Treatment of patients with multiple myeloma than 65–70 years of age and the role of maintenance therapy after transplantation stem cells
Journal Title: OncoReview - Year 2011, Vol 1, Issue 4
Abstract
Treatment of myeloma has changed significantly in the past decade as results of better understanding of disease biology, more effective treatments, and improved supportive care. Autologous stem cell transplantation (SCT) is an effective treatment for myeloma and remains a critical component in its management. Given the potential impact of therapy on stem cell collection, initial treatment decision in myeloma still depend on the patient’s transplant eligibility. The goals of initial therapy remain rapid disease control allowing for reversal of complications, as well as reduction in the risk of early death– all with minimal toxicity. The introduction of new drugs such as thalidomide, bortezomib, and lenalidomide has enabled us to achieve this goal, and combinations of these drugs have also led to unprecedented response depth. In addition, the drugs are newer being explorated as maintenance therapy following SCT. This review summarizes the current approach to the treatment of newly diagnosed myeloma in transplant-eligible patients.
Authors and Affiliations
Artur Jurczyszyn
Keywords
Related Articles
- EP ID EP53121
- DOI -
- Views 234
- Downloads 0
Krwioplucie – rak czy zatorowość płucna?
Pacjenci onkologiczni to grupa o zwiększonym ryzyku wystąpienia zatorowości płucnej. Zarówno w obrazie klinicznym zatorowości płucnej, jak i w przebiegu choroby rozrostowej może wystąpić krwioplucie. Jest ono zawsze obja...
Skin of sailor: cutis rhomboidalis nuchae, actinic keratosis, squamous cell carcinoma and basal cell carcinoma. Case report
Chronic exposure to environmental ultraviolet radiation (UVR) plays a key role both in photocarcinogenesis and induction of accelerated skin ageing. Sailors commonly experience a significant number of cutaneous problems,...
Cardiooncological balance in a 75-year-old male with a hepatocellular carcinoma CS IV and a congestive heart failure NYHA III „de novo”
The case reports about a 75-years-old man without a previous medical history, in whom a heart failure NYHA III de novo was diagnosed together with persistent atrial fibrillation and hepatocellular carcinoma in clinical s...
Imaging for Cardiotoxicity: Many Issues, Many Questions
Tumor lysis syndrome
Tumor lysis syndrome is a life-threatening oncological emergency occurring in response to chemotherapy or spontaneously as a result of massive and rapid breakdown of malignant cells. The release of their contents into ci...